Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457304 | 0.85 | ALDH1A1 (0.39) | GABRA1GABRB2AHRALDH1A1CYP3A4 | |
| SCHEMBL17649223 | 0.81 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL17650573 | 0.81 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL7117793 | 0.78 | AR (0.36) | GABRA1GABRB2 | |
| SCHEMBL17648937 | 0.76 | GABRA1 (0.33) | GABRA1GABRB2ALDH1A1CYP3A4TSHR | |
| SCHEMBL248024 | 0.75 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL6151901 | 0.74 | RAPGEF4 (0.41) | RAPGEF4AHRALDH1A1CYP3A4TSHR | |
| SCHEMBL11758054 | 0.72 | RAPGEF4 (0.39) | RAPGEF4AHRALDH1A1CYP3A4TSHR | |
| SCHEMBL11758059 | 0.72 | RAPGEF4 (0.39) | RAPGEF4AHRALDH1A1CYP3A4TSHR | |
| SCHEMBL1457069 | 0.72 | GABRA1 (0.50) | GABRA1GABRB2ALDH1A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-9321796-B2 | Galactopyranosyl derivatives useful as medicaments | UNIVERSITEIT GENT (BE) | 2016-04-26 | — | — | US | disclosed |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | AMBICION CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| WO-2014001204-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIVERSITEIT GENT (BE) | 2014-01-03 | — | — | WO | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | GABRA1 2786/4885GABRB2 2428/4885RAPGEF4 3409/4885 |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | GABRA1 727/4885GABRB2 780/4885RAPGEF4 2033/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GABRA1 2266/4885GABRB2 2346/4885RAPGEF4 3913/4885 |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | B3GAT3, GALR3, ST6GAL1 | GABRA1 3069/4885GABRB2 3018/4885RAPGEF4 4004/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | GABRA1 2786/4885GABRB2 2428/4885RAPGEF4 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.